<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">38403281</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0253-9624</ISSN><JournalIssue CitedMedium="Print"><Volume>58</Volume><PubDate><Year>2024</Year><Month>Feb</Month><Day>23</Day></PubDate></JournalIssue><Title>Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]</Title><ISOAbbreviation>Zhonghua Yu Fang Yi Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Infection status and Molecular types of Rhinovirus among Cases of Acute Respiratory Tract Infections in Luohe City, Henan Province, from 2017 to 2022].</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>8</EndPage><MedlinePgn>1-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112150-20231207-00411</ELocationID><Abstract><AbstractText><b>Objective:</b> To understand the infection status and molecular types of rhinovirus (RV) among cases of Acute Respiratory Infections (ARIs) in Luohe City, Henan Province, from 2017 to 2022. <b>Methods:</b> From October 2017 to June 2022, clinical and epidemiological data were collected from 2 270 cases of ARIs at Luohe Central Hospital in Henan Province. Throat swab specimens were obtained from these cases. Real-time quantitative polymerase chain reaction (qPCR) was used to screen for RV-positive specimens. Subsequently, the positive samples were subjected to nested reverse transcription polymerase chain reaction (nested RT-PCR) to amplify the full-length VP1 region. Using the MEGA software, along with 169 RV reference strains recommended by the International Committee on Taxonomy of Viruses, a phylogenetic tree was constructed to determine RV types. <b>Results:</b> Among the 2 270 cases of ARIs, there were 1 283 male cases (56.52%). The median age (<i>Q<sub>1</sub></i>, <i>Q<sub>3</sub></i>) was 3 (1, 6) years, with the population under 5 years old accounting for 68.59% (1 557/2 270). RV was detected in 137 cases (6.04%), of which 68 cases (49.64%) showed co-detection with other viruses, with the most common being co-detection with enterovirus, accounting for 14.60% (20/137). The RV detection rates in the age groups of 0~4 years, 5~14 years, 15~59 years, and≥60 years were 6.42% (100/1 557), 4.69% (21/448), 3.80% (6/158), and 9.35% (10/107), respectively, with no statistically significant differences (<i>χ</i><sup>2</sup>=5.310, <i>P</i>=0.150). The overall detection rates of RV before (2017-2019) and during (2020-2022) the COVID-19 pandemic showed no statistically significant difference (<i>χ</i><sup>2</sup>=1.823, <i>P</i>=0.177). A total of 109 VP1 sequences were obtained, including 62 types. Among them, RV-A, RV-B, and RV-C had 42, 3, and 17 types respectively. <b>Conclusion:</b> RV is one of the predominant pathogens in ARIs cases in Luohe City, Henan Province, from 2017 to 2022. Multiple types of RV co-circulate without any apparent dominant type.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Y G</ForeName><Initials>YG</Initials><AffiliationInfo><Affiliation>Medical School, Anhui University of Science and Technology, Huainan 232001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>B C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Z B</ForeName><Initials>ZB</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Expanded Immunization Programme, Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Z B</ForeName><Initials>ZB</Initials><AffiliationInfo><Affiliation>Health Testing Laboratory, Luohe Center for Disease Control and Prevention, Luohe 462000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>H R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Cardiovascular Institute of Luohe, Luohe Central Hospital, Luohe 462000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>H L</ForeName><Initials>HL</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Center for Disease Control and Prevention of Luohe Central Hospital, Luohe 462000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>J H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y D</ForeName><Initials>YD</Initials><AffiliationInfo><Affiliation>Center for Disease Control and Prevention of Luohe Central Hospital, Luohe 462000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Centers for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZDGWXFTF23-04</GrantID><Agency>National Major Public Health Project</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Yu Fang Yi Xue Za Zhi</MedlineTA><NlmUniqueID>7904962</NlmUniqueID><ISSNLinking>0253-9624</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>目的：</b> 了解河南省漯河市2017—2022年急性呼吸道感染（ARIs）病例中鼻病毒（RV）的感染状况及其分子型别组成。 <b>方法：</b> 于2017年10月至2022年6月，收集河南省漯河市中心医院2 270例ARIs病例的临床和流行病学资料，并采集病例咽拭子标本，采用实时荧光定量聚合酶链式反应（qPCR）筛选RV阳性标本，随后对阳性标本使用巢式逆转录聚合酶链式反应（nested RT-PCR）扩增VP1区全长，并使用MEGA软件结合国际病毒分类委员会推荐的169条RV参考株序列构建系统进化树以确定RV分型。 <b>结果：</b> 2 270例ARIs病例中，男性病例1 283例（56.52%）；年龄<i>M</i>（<i>Q<sub>1</sub></i>，<i>Q<sub>3</sub></i>）为3（1，6）岁，5岁以下人群占68.59%（1 557/2 270）；137例病例（6.04%）检出RV，其中68例病例（49.64%）与其他病毒合并检出，与肠道病毒的合并检出最常见，占14.60%（20/137）。0~4岁、5~14岁、15~59岁和≥60岁年龄组中RV检出率分别为6.42%（100/1 557）、4.69%（21/448）、3.80%（6/158）和9.35%（10/107），差异无统计学意义（<i>χ</i><sup>2</sup>=5.310，<i>P</i>=0.150）。新型冠状病毒感染疫情前（2017—2019年）和期间（2020—2022年），RV总体检出率差异无统计学意义（<i>χ</i><sup>2</sup>=1.823，<i>P=</i>0.177）。共获得109条VP1序列，包含62个型别，其中RV-A、RV-B和RV-C三个种分别检出42、3和17个型别。 <b>结论：</b> RV为2017—2022年河南省漯河市ARIs病例中主要流行的病原体之一，存在多个RⅤ型别共流行，无明显优势型别。.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>25</Day><Hour>20</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38403281</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112150-20231207-00411</ArticleId></ArticleIdList></PubmedData></PubmedArticle>